Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb Randomized Study of Intermittent Versus Continuous Androgen Deprivation Therapy Using ELIGARD 22.5 mg 3-month Depot in Subjects With Relapsing and Locally Advanced Prostate Cancer Who Are Responsive to Such Therapy

NCT00378690 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00378690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00378690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb Randomized Study of Intermittent Versus Continuous Androgen Deprivation Therapy Using ELIGARD 22.5 mg 3-month Depot in Subjects With Relapsing and Locally Advanced Prostate Cancer Who Are Responsive to Such Therapy
Lead sponsor
Astellas Pharma Inc
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2006
Completion date
December 31, 2012
Enrollment
706 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer